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LETTERS TO THE EDITOR
Vascular calcification in
patients with preserved renal
function
To the Editor: Vascular calcification was the subject
of a recent review article [1], the subtitle of which was:
Does preventing bone disease cause arterial disease? The
authors discuss the possible link between calcium intake
and cardiovascular disease. This link may be particularly
important in patients with renal failure, but mention was
made to the fact that a similar relation may exist in pa-
tients not on dialysis [2]. We have studied plasma calcium
and phosphorus in 110 patients with coronary atheroscle-
rosis and relatively preserved renal function (plasma cre-
atinine smaller than 2 mg/dL) that underwent coronary
angiography after an acute coronary syndrome [3]. Coro-
nary artery disease burden was significant correlated with
plasma calcium, but not with plasma phosphorus. A pos-
sible cut-off level for plasma calcium at 2.20 mmol/L was
established [3]. These results are at odds with a previ-
ous report that showed that plasma phosphorus, but not
plasma calcium, had an independent positive association
with the angiographic severity of coronary disease, in a
cohort of 376 stable patients without known renal disease
[4]. It is unclear if subclinical renal failure (a condition in
which phosphorus and calcium metabolism is changed)
may have existed in this latter cohort. Plasma calcium
[3] or plasma phosphorus [4] may be correlated with the
severity of coronary atherosclerotic disease in patients
with relatively preserved renal function [3], or in patients
without known renal disease [4]. This may indicate a need
for a reassessment of calcium supplementation, not only
in dialysis patients, but also in patients with preserved
renal function.
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Sevelamer-induced acidosis
To the Editor: Brezina et al [1] ignore an important
but neglected aspect of gastrointestinal physiology in at-
tributing sevelamer-induced acidosis to replacement of
intestinal phosphate, bicarbonate, and bile acid anions
by chloride carried on the resin. These three anions are
minor luminal constituents in the distal large intestine,
where sevelamer reaches its final equilibrium with in-
testinal fluids before expulsion from the body. The pre-
dominant anions here are short-chain fatty acid anions
(SCFAA)—acetate, propionate, and n-butyrate, with to-
tal concentrations of over 150 mmol/L, constituting over
70% of luminal anions [2–4]. These SCFAA are derived
from bacterial fermentation of food residues (mainly car-
bohydrate) and are bicarbonate precursors, normally be-
ing absorbed by the intestinal mucosa and incorporated
into intermediary metabolism. Every mole of SCFAA re-
moved from the body by sevelamer, and replaced by chlo-
ride from the resin, thus represents a loss of a mole of
bicarbonate from the body and its replacement by chlo-
ride, equivalent to a gain by the body of a mole of hy-
drochloric acid; the amounts are far greater than would
be generated by the resin’s uptake of other anions from
large bowel contents.
This uptake of SCFAA by an anion-exchange resin
passing through the gut was shown over 40 years ago,
when normal subjects were fed four different anion-
exchange resins [5]. Recovered from stool, the resins’
anion-exchange capacity was 66% to 84% unaccounted
for by chloride, sulphate, phosphate, bicarbonate, and car-
bonate, and must have been SCFAA, which we were then
unable to measure.
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Reply from the Authors
Thank you for calling our attention to the importance
of anion exchange of chloride for short-chain fatty acid
anions (SSFAA) as a potential mechanism of sevelamer-
induced metabolic acidosis. To the best of our knowl-
edge, no data have been published regarding the relative
binding affinity of sevelamer hydrochloride (a quater-
nary amine anion exchange resin) for the various an-
ions present in the intestinal lumen (phosphates, sulfates,
bicarbonate, carbonate, citrate, bile acids, acetate, and
other SSFAA). However, it seems likely that binding
of SSFAA by sevelamer in the large intestine may well
be a major factor in the genesis of sevelamer-induced
metabolic acidosis, as you suggest. Final equilibration in
the gut with binding of SSFAA, bicarbonate, and bile
acids to the sevelamer resin, resulting in displacement of
phosphate, may also help to explain the well known dis-
crepancy between the in vitro and in vivo phosphate bind-
ing efficacy of sevelamer. In dialysis patients with refrac-
tory hyperphosphatemia, it has been recommended that
sevelamer and calcium acetate or calcium carbonate be
used concomitantly [1]. However, it is theoretically pos-
sible that simultaneous use of calcium-based phosphate
binders containing acetate or carbonate could further re-
duce the phosphate-binding efficacy of sevelamer. These
considerations suggest that an optimal strategy may be to
alternate use of sevelamer and calcium-based phosphate
binders with different meals during the day. Moreover, if
sodium bicarbonate supplements are needed to maintain
serum bicarbonate above 22 mEq/L, as recommended
by K/DOQI guidelines [2], the oral bicarbonate supple-
ment should probably not be ingested at the same time
as sevelamer to avoid competition between bicarbonate
and phosphate for binding to the resin.
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Kidney function itself, and not
cystatin C, is correlated with
height and weight
To the Editor: In a recent issue of this journal [1],
Knight et al presented data from a large population study
on factors influencing serum cystatin C concentrations in
adults. After adjustment for uncorrected creatinine clear-
ance (in mL/min), multivariate linear regression analysis
yielded a significant positive correlation of cystatin C with
age, male gender, weight, height, cigarette smoking, and
C-reactive protein (CRP) levels.
Traditionally, glomerular filtration rate (GFR) is nor-
malized to 1.73m2 body surface area (BSA) [2], which
is of particular importance in growing subjects. There-
fore, almost all papers correlating cystatin C with a gold-
standard GFR were indexed to BSA. When looked at,
anthropomorphometric data did not influence the cor-
relation between GFR normalized for BSA and serum
cystatin C [3].
It is therefore not surprising that Knight et al [1] identi-
fied height and weight—the chief determinants of BSA—
as confounding variables for both cystatin C and creati-
nine when studying correlation with uncorrected GFR.
It would be interesting to see which effect normalization
of creatinine clearance to BSA has on the other correla-
tions reported. Their large cohort is certainly particularly
well suited to identify factors weakly influencing serum
cystatin C concentration that have been missed so far.
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